Novavax's Gregory Glenn on biotech's vaccine race

Biotech companies around the world were stepping up efforts to fight coronavirus. 

Several announced they were ready for human trials. 

CGTN's Asieh Namdar talked to Dr Gregory Glenn, president of Novavax's Research and Development, to see what to expect in the Phase 1 human trial starting in mid-May.